Does vitiligo happen there at all?
Yes, and the guidelines have a name for it. The NHS page I read lists the groin and the genitals among the areas vitiligo most commonly affects. British and international guidelines call it mucosal vitiligo, meaning the oral or genital mucosae. The 2023 international recommendations put genital involvement on their assessment checklist. Evidence Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
It is the same condition as the patches anywhere else on you, in a place you do not show people. The patient pages name it in a list and move on, which is why you may have found nothing when you looked. I went further into the guidelines: there is a category for it, and it is on the checklist clinicians are asked to work through.
Considerations
- Depends on you
I looked for a figure for how often this happens, and in whom, and found none. None of them can tell you that the patch you can see is vitiligo. The NHS says a GP diagnoses vitiligo by examining the skin, so that part needs a person, not a page.
Questions for your dermatologist or GP
Is this vitiligo, or is it something else?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Will you look at this area, or refer me to someone who will?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Could a partner think it is an STI? Can they catch it?
No, and nothing about it is passed on by sex. The NHS says it plainly: vitiligo is not caused by an infection, and you cannot catch it from someone else who has it. The British vitiligo guideline I read describes autoimmunity as a contributor to how vitiligo develops. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Whether you are contagious, or will be thought so, is one of the questions readers ask most. Here it usually arrives as a question about a partner. The same is true of lichen sclerosus, the other common cause of white patches in that area. The NHS says it is not caused by an infection and cannot be spread to other people through close contact, including sex. So the answer does not depend on which of the two you turn out to have.
Considerations
- Depends on you
That settles what can be passed on. It does not settle what you want to say, or when. I put the scripts for that conversation on Telling someone rather than a worse version of them here. The British guideline reports an earlier review finding a potential negative impact on intimacy and sexual functioning, and tells clinicians to raise the psychosocial side. Nobody else gets to set your timing.
Questions for your dermatologist or GP
Can you write down in one line what this is, so I can show someone?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Can we talk about the part of this that is affecting my relationship?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Is every white patch there vitiligo?
No. The British vitiligo guideline I read lists genital lichen sclerosus among the conditions that can be mistaken for vitiligo, alongside eczema, psoriasis and several others. The NHS says the genitals are where lichen sclerosus appears most often. Telling them apart matters, because lichen sclerosus can scar over time and raises the risk of cancer of the vulva, penis or anus. Evidence Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The NHS describes lichen sclerosus patches as itchy, white, smooth or crinkled, and easily damaged. It says to see a GP about an itchy white patch on your genitals. I read its vitiligo description beside that one: the patches do not usually cause discomfort, although they may occasionally itch. The 2012 international classification consensus is blunter. Where vitiligo shows up in one mucosal site alone, and especially a genital one, it says lichen sclerosus should be addressed by biopsy.
Considerations
- Depends on you
Those two descriptions overlap enough that looking is not always enough. A 2026 study of vulvar biopsies I read found the two conditions together in most of the women it examined. It reported that even under a microscope the two can be hard to separate. Nothing here says which one you have.
Questions for your dermatologist or GP
Could this be lichen sclerosus as well as, or instead of, vitiligo?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What would tell the two apart in my case?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
It itches. Is that just the vitiligo?
Probably not, and it is worth reporting rather than putting up with. I read a 2026 series of 36 women with vitiligo confirmed on a vulvar biopsy. In it, 23 of them, or 64 per cent, also had lichen sclerosus or a related inflamed skin condition. The pairing is not new: the 2012 international consensus already recorded the two being reported together. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
The itch tracked that second condition rather than the vitiligo. It was reported by 21 of the 23 women who had one, against 6 of the 13 who did not. The authors concluded that women with symptoms and biopsy-proven vulvar vitiligo usually have another skin condition as well.
Considerations
- Depends on you
These were 36 women whose skin was biopsied at all, so they were already unusual. It was vulvar skin only, and the study says nothing about penile or other genital skin. Three of the seven women with vitiligo alone still reported pain or itch, so vitiligo by itself is not silent for everyone. The 2012 consensus called a link between the two a possibility, not a finding.
Questions for your dermatologist or GP
The itch is the part that bothers me. What could be causing that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence and update context
This optional layer shows the evidence boundary I reviewed as of 2026-09-19.
- What this evidence supports
- It is the same condition as the patches anywhere else on you, in a place you do not show people. The patient pages name it in a list and move on, which is why you may have found nothing when you looked. I went further into the guidelines: there is a category for it, and it is on the checklist clinicians are asked to work through.
- What it does not establish
- I looked for a figure for how often this happens, and in whom, and found none. None of them can tell you that the patch you can see is vitiligo. The NHS says a GP diagnoses vitiligo by examining the skin, so that part needs a person, not a page.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
No. The British vitiligo guideline I read lists genital lichen sclerosus among the conditions that can be mistaken for vitiligo, alongside eczema, psoriasis and several others. The NHS says the genitals are where lichen sclerosus appears most often. Telling them apart matters, because lichen sclerosus can scar over time and raises the risk of cancer of the vulva, penis or anus.
- Age range
- Not reported
- Condition subtype
- Not reported
- Severity or extent
- Not reported
- Sample size
- Not reported
- Geography and care setting
- Both cited pages are NHS patient information written for UK care, so their referral route is a UK one. Neither reports a study population.
- Skin tone or phototype
- Not reported
- Race
- Not reported
- Ethnicity
- Not reported
- Body sites
- The vulva and anus, and the foreskin and end of the penis, are where the NHS says lichen sclerosus most often appears. The NHS lists the groin and genitals among the areas vitiligo commonly affects.
What that means for this page: These are patient-information pages, not studies. They establish that more than one condition causes white patches in this area and that one of them scars and carries a cancer risk. They estimate no risk for any person, and neither page can say which condition a reader has.
Probably not, and it is worth reporting rather than putting up with. I read a 2026 series of 36 women with vitiligo confirmed on a vulvar biopsy. In it, 23 of them, or 64 per cent, also had lichen sclerosus or a related inflamed skin condition. The pairing is not new: the 2012 international consensus already recorded the two being reported together.
- Age range
- Women aged 18 or over, with a median age of 56. The study reports no upper age and no age band.
- Condition subtype
- Vulvar vitiligo defined on the slide, by absent or rare pigment cells on HMB-45, Sox-10 or Melan-A staining. Cases were then split by whether the slide also showed a lichenoid condition.
- Severity or extent
- Not reported
- Sample size
- 36 women, identified from one pathology database. 23 of them had lichen sclerosus or lichenoid dermatitis at the same time, 7 had otherwise normal skin, 5 had lichen simplex chronicus and 1 had spongiotic dermatitis.
- Geography and care setting
- Australian hospital pathology records, read back with the matching clinical notes. Everyone in the series had skin a clinician chose to biopsy.
- Skin tone or phototype
- Not reported
- Race
- Not reported
- Ethnicity
- Not reported
- Body sites
- Vulvar skin only. The study reports nothing about penile skin or any other genital site.
What that means for this page: This describes 36 women whose vulvar skin was biopsied, not people with vitiligo in general. It cannot say how often the two conditions overlap in anyone who is never biopsied, and it predicts nothing about one person. It sets no treatment and names no product.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Pigment Cell & Melanoma Research (Ezzedine K, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports separating segmental vitiligo from nonsegmental forms and recognizing mixed and initially unclassified presentations. Classification is a clinical and longitudinal judgment. Its section on the Koebner phenomenon supports defining that phenomenon as patches developing at sites of previously unaffected skin that was specifically injured. It endorses the Vitiligo European Task Force classification of that phenomenon into history-based, clinical-observation-based and experimentally induced forms. Its section on mucosal vitiligo defines that term as the oral or genital mucosae. Where the patches are at one site alone, and especially a genital one, that section says a differential diagnosis of lichen sclerosus should be addressed by biopsy. It records that genital lichen sclerosus and vitiligo have been reported together.
What it does not support
It does not support self-classification from symmetry, one patch or a photograph, and it does not predict an individual response. On the Koebner phenomenon it records a general impression that the phenomenon and disease stability are related, then states that objective data are lacking. It also says scientific evidence is lacking for attributing vitiligo to daily friction from washing, dressing, personal care, sports, occupational activity or pressure from clothing. On lichen sclerosus it cites one reference from 2000 and calls a link a possibility, not a finding. It counts nothing and gives no rate.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- American Academy of DermatologyPatient education · Patient education, tier 5Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The page carries a line thanking Incyte Dermatology for its support. Incyte sells a topical medicine for vitiligo, so the page is not independent of a commercial interest in the subject, even though the AAD states that it developed the content itself.
What this source supports
Supports that vitiligo can develop anywhere on a person’s skin, and that the patches usually appear first on the face, arms, hands or feet. It supports that some people lose color in areas called mucous membranes, which the page says includes the genitals and the inside of the mouth and nose. It supports that vitiligo can affect the hair, and that it can develop inside the ear.
What it does not support
It is a patient-education page rather than a study. It counts nothing: it does not say how many people lose color in the genital area, in whom, or when in the course of the condition. It does not diagnose a reader, and it names no treatment for any site. It is a US page, last updated 15 April 2026, and it acknowledges support from Incyte Dermatology.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Health Service (UK)Patient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a UK national health service account of vitiligo written for patients. It supports that the areas most commonly affected include the mouth and eyes, fingers and wrists, armpits, groin, genitals and the inside of the mouth. It supports that vitiligo is not caused by an infection and that you cannot catch it from someone else who has it. It supports that vitiligo does not cause discomfort to the skin, such as dryness, but that the patches may occasionally be itchy. It supports that a GP can diagnose vitiligo after examining the affected skin. It supports that the lack of melanin can turn the hair in an affected area white or grey.
What it does not support
It is a patient-information page, not a study, and it reports no numbers for any body site. It does not establish how common genital involvement is, and it cannot tell a reader that a patch they can see is vitiligo. It is written for UK care, so its diagnosis and referral route are UK ones. Its own footer records a last review of 22 March 2023 and a next review due 22 March 2026, so at the date it was verified here the page was five months past the date the NHS set for reviewing it.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Health Service (UK)Patient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that lichen sclerosus is a skin condition causing itchy white patches, most commonly on the genitals. It supports that the patches are usually itchy, white, smooth or crinkled, and easily damaged. It supports that they most often appear around the opening to the vagina and the anus, or on the foreskin and end of the penis. It supports that lichen sclerosus is not caused by an infection and is not contagious, and that it cannot be spread to other people through close contact, including sex. It supports that affected skin can become scarred and tight over time. It supports that lichen sclerosus increases the risk of getting cancer on the vulva, penis or anus, and that the NHS calls that risk low. It supports the NHS advice to see a GP about an itchy white patch on the genitals or skin. It supports that it is much more common in women over 50 and that people with white, brown or black skin can get it.
What it does not support
It is a patient-information page, not a study, and it reports no numbers at all. It does not establish how often lichen sclerosus and vitiligo occur together, and it cannot tell a reader which of the two they have. Its self-care and treatment sections are written for people who already have the diagnosis; I do not use them here, because a treatment step needs a diagnosis a page cannot make. It is written for UK care. Its footer records a last review of 9 December 2024 and a next review due 9 December 2027.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of Lower Genital Tract Disease (du Plessis J, Scurry J, Toon CW, et al.)Observational study · Supporting research, tier 3Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The authors declare they have no conflicts of interest, and the study reports on hospital pathology records rather than on a product.
What this source supports
Supports a review of vulvar biopsies showing vitiligo, defined by absent or rare pigment cells on staining, in 36 women with a median age of 56. It supports that 23 of them, or 64 per cent, also had lichen sclerosus or lichenoid dermatitis diagnosed at the same time. It supports that 7, or 19 per cent, showed otherwise normal skin, 5 had lichen simplex chronicus and 1 had spongiotic dermatitis. It supports that itch was more frequent in the group with a second lichenoid condition, at 21 of 23 against 6 of 13. It supports that 3 of the 7 women with vitiligo alone on the slide still reported pain, itch, or both. It supports the authors’ conclusion that women with symptoms and biopsy-proven vulvar vitiligo usually have an additional skin condition, and that separating overlapping conditions is complicated even on the slide.
What it does not support
It is a retrospective series of 36 people identified from one pathology database, not a population. Everyone in it had skin that a clinician chose to biopsy, so it cannot say how common either condition is, how often they overlap in people who are never biopsied, or how often vitiligo there itches. It is vulvar skin only and reports nothing about penile or other genital skin, and its median age is 56. It sets no treatment, names no product, and cannot tell a reader which condition they have.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.